Dive Brief: - Bicycle Therapeutics said Tuesday that it will lay off 30% of its workers and “deprioritize” an experimental antibody-drug conjugate that has been seen as a possible threat to Pfizer’s bladder cancer drug Padcev. - The decision was driven by discussions with the Food and Drug Administration and other regulators about the approval path for the therapy, known as zelenectide pevedotin. ...